AKT1 and cancer: Although the study of BRAF and its transcript variants in this cancer type is still in its infancy, we propose that the BRAF‐204 transcript might sustain not only the ERK pathway but also the PI3K/AKT pathway by sponging the oncosuppressive miR‐423 and relieving its targeting of PDPK1.